Building a biotech start-up: getting IP, financing and structure right

Key takeaways

• Define the asset first. In biotech, that is rarely just a patent. More often, it is a bundle of patentable technology, know-how, data, SOPs, materials and a development plan.

• Decide early what should be patented, what should remain confidential and what must be secured by contract. Not every biotech start-up needs a broad patent portfolio, but every biotech start-up needs a clear IP strategy.

• Build the company so it can be financed. The legal form, cap table, shareholders’ agreement, vesting and, where relevant, a later VSOP should be designed together from the outset.

• Size funding rounds around specific milestones. In biotech, investors do not usually finance an abstract vision. They finance clearly defined steps that reduce technical or regulatory risk, such as robust preclinical data, CMC progress or a more credible regulatory pathway.

Many biotech start-ups do not fail because the science is weak. They fail because a promising technology is never turned into a robust business. That is where most problems arise: around IP and data, in the pre-incorporation phase, in the financing logic, in the cap table and in the question which contracts really need to be in place early.

This article is for founders in biotech and Life Sciences who want to turn technology into a financeable company. It explains which questions need to be addressed, in which order, how rights, financing and governance fit together and why issues such as shareholders’ agreements, vesting, VSOP, patent licensing and patent assignment are not secondary details in biotech. They are part of the foundation.

How does technology become an investable asset?

The first step is to define, with precision, what actually makes the company valuable.

In biotech, the asset is rarely just a single patent. More often, it consists of a combination of patentable inventions, know-how, data, materials, assays, software, processes or manufacturing information. If that package is defined too loosely, problems usually surface later in due diligence, venture capital discussions, licensing negotiations or strategic partnerships.

That is why founders should distinguish early between hard IP and soft IP. Hard IP typically includes patents and other formal rights. Soft IP includes know-how, SOPs, datasets, development information, software, protocols and trade secrets. In Life Sciences, these soft-IP elements are often just as important in financing rounds and collaborations as the formal patent position.

Many founders ask at this stage whether they need a patent at all. The answer is not always yes. Not every biotech or Life Sciences start-up needs a broad patent portfolio. Some businesses derive more value from data, software, processes, platform know-how, speed of development or exclusive access to materials than from a single registered right. In other cases, however, a weak patent position can materially reduce financeability, especially where the company is built around therapeutics, diagnostics or licensable core technology.

The more useful question is therefore not simply: Do we have a patent? It is: Which IP strategy supports our business model? That includes deciding which parts of the technology should be patented, which are better protected as trade secrets, which datasets matter for future partnering or regulatory pathways and how all of this aligns with financing and commercialization.

In biotech, founders also need to make a deliberate choice between disclosure and confidentiality. Patents create formal exclusivity, but they generally require disclosure. Once a company chooses the patent route, it must accept that some technical knowledge will be made public. Trade secrets can be highly valuable, but only if confidentiality is protected in practice through contracts and internal controls. The real strategic question is therefore often not just “patent or not”, but: Which elements of the technology should be disclosed and patented, and which should deliberately remain confidential? Where confidentiality is the better strategy, the company will usually need technical and organizational safeguards as well, such as access controls, role-based permissions, internal policies, documentation standards and SOPs. In Life Sciences, these should not be introduced only once investors or partners ask for them.

The question of where to file a patent should also not be answered reflexively. The right answer is usually driven less by abstract “important markets” and more by the actual commercial logic: where relevant competitors are based, where future partners or licensees are likely to be approached, where development, manufacturing or commercialization may take place and which filing strategy is realistic for an early-stage company. In practice, early-stage biotech is often less about maximum territorial coverage and more about disciplined prioritization.

Which rights and pre-incorporation liability risks need to be addressed?

Before incorporation, rights analysis and pre-incorporation risk should be treated as part of the same exercise.

Founders first need to establish where the relevant rights sit and in what form the future company will be able to use them. That applies not only to patents, but also to data, materials, software, know-how and third-party development contributions. In Life Sciences, gaps frequently arise because not all contributions automatically end up in the company.

If IP already exists before incorporation, founders need to decide whether it should be assigned to the company or licensed into it. Both models can work. The better choice depends on the asset, the financing logic and the intended commercialization strategy. For a deeper look at that distinction, BIO.LAW has separate articles on licensing a patent and assigning a patent. Where the start-up emerges from a university or research institution, additional issues arise around tech transfer and the institutional IP framework. We address those separately in our article on university and research spin-outs.

A second issue is often underestimated: many projects become operational before the company formally exists and can act in its own name. At that stage, founders may already engage consultants, use lab capacity, prepare grant applications, procure materials or speak with investors and industry partners. The risk is that obligations are taken on before there is a company capable of bearing them. If this is handled too early or too loosely, founders may create personal exposure. In practical terms, founders should clarify early who is acting, in whose name, which contracts can already be entered into and from which point the future company can assume those relationships.

How do you build the right financing and ownership structure?

In biotech, financing is built around value-inflection points, not around an abstract growth plan.

Early rounds are rarely about raising as much money as possible. They are about calibrating capital so that each round reduces a specific block of uncertainty. In biotech, that usually means more than “general progress”. It means answering concrete questions: Can the technology be shown to work reproducibly? Are there robust preclinical data? Is the manufacturing path technically controllable? Is there a plausible regulatory pathway? And will the asset be more attractive for the next financing round, a license deal or a strategic partner afterwards than it is today?

That is one of the central differences between biotech financing and financing in many other sectors. Capital is used primarily for risk reduction, not simply for rapid growth. Investors are therefore not funding science in the abstract. They are funding the prospect that scientific progress will translate into a measurable increase in company value. The more precise question is not simply: How much capital do we need? It is: What level of capital gets us to which defensible data or development position?

This is also where many biotech start-ups run into structural difficulty. They often do not fail because the technology is necessarily weak, but because funding cannot be secured across a long, high-risk development path. For investors, biotech is often harder than other sectors: capital is tied up for longer, technical and regulatory risk is higher and a quick way in or out is often unrealistic. That is one reason why raising sufficient capital for a biotech start-up is usually harder than for less research-intensive businesses.

There is only limited value in responding to that challenge with a better pitch alone. What matters more is a structure that allows investors to assess risk with more precision. That usually means breaking financing into credible milestones rather than asking for a single oversized round. Each round should be tied to a specific value driver, such as a defined data package, a meaningful preclinical proof point, a CMC step or a more credible regulatory path. It also helps to combine funding sources deliberately, for example grants, strategic collaborations, licensing structures, public innovation programs and classic venture capital. Just as importantly, the company needs to become documentation-ready and diligence-ready early. In biotech, financeability can deteriorate quickly if chain of title, data integrity, material flows or governance are not well prepared.

Different development stages therefore require different financing profiles. In a very early phase, founders may rely on their own funds, grants, incubators and public innovation programs while building technical feasibility, the data package and the asset structure. Once the company enters a stage where outside investors are testing scalability, commercialization potential and exit logic more closely, expectations change. At that point, good science alone is not enough. The company needs to explain which milestones will be achieved before the next round, how they translate into a stronger valuation case and which documentation, rights position and governance framework support that progression.

A preclinical company therefore usually needs different investors, different materials and a different narrative from a business with strong animal data, a credible clinical pathway or a platform-based licensing model. In an early preclinical phase, the central question is often whether the asset is scientifically and technically robust. Later, the emphasis shifts towards CMC, regulatory path, partnerability, licensability and scalability. In biotech, financing is strongest when it follows a coherent development logic rather than a generic growth logic.

In practical terms, founders should not treat financing as a search for investors alone. They should treat it as the translation of science into financing steps. For each round, they should be able to explain: Which milestone is being funded? Which risk does it reduce? Which rights, documents and data need to be in place? And why does that progress make the next round, a licensing discussion or a strategic deal more realistic?

Which legal form is best suited to a biotech start-up?

For many biotech start-ups, a limited liability company is the most convincing basic structure because it concentrates risk, financing and IP in one vehicle.

The first reason is liability protection. Biotech businesses often assume substantial economic risk early, through lab and development work, hiring, IP costs, material procurement, regulatory preparation and sometimes first collaboration agreements. A limited liability structure separates those business risks, in principle, from the founders’ personal assets. That is not mere formality. It is a central protection mechanism in a capital-intensive and high-risk sector.

The second reason is investor readiness. Venture capital investors and other professional capital providers typically invest into structures where shareholdings, financing rounds, dilution, exit mechanics and governance can be documented clearly. Limited liability companies usually perform better here than partnership-style or mixed structures. They support a cleaner cap table and a more workable implementation of shareholders’ agreement mechanics, vesting, employee participation and later VSOP structures.

The third reason is IP holding capacity. In biotech, patents, license rights, know-how, data, materials and other assets often need to be bundled in one clean legal entity. A limited liability company usually serves this purpose better because it can act as a clear holder of rights, contracts and financing. That becomes especially important where the start-up needs to license patents, receive patent assignments or act as a licensor itself.

The fourth reason is governance. Biotech start-ups often need to structure decisions early that go beyond the everyday life of a small founding team: new financing rounds, reserved matters, collaboration agreements, strategic partnerships, exit scenarios or changes in management. Corporate entities usually provide a clearer legal framework for governance bodies, representation, resolutions and shareholder rights.

In Germany, that is one reason why the GmbH is often the default. It combines limited liability with a structure that is well understood by the market and generally works well for IP holding, financing rounds and governance arrangements. In very early phases, a UG (haftungsbeschränkt) can sometimes be used as an interim solution, particularly where founders want to become operational quickly with lower initial capital. In practice, however, it is often more of an early-stage bridge than a long-term target structure, because many investors and transaction counterparties prefer a GmbH.

In other jurisdictions, limited companies or corporations often serve a comparable function. What matters is less the national label and more the legal quality of the structure: separation of liability, ability to accommodate investment, workable governance and the capacity to hold both IP and financing in one vehicle.

The legal form should therefore never be chosen in isolation. It is always also a decision about how the start-up will bear risk, bundle rights, admit investors and document later stages of development. A form that is cheap or fast to set up is not automatically the better form if it later creates friction around venture capital, licensing, collaborations or the IP set-up.

Which documents need to be in place early?

Once the legal form, asset and financing logic are clearer, those decisions need to be translated into a robust set of documents.

The starting point is usually the articles of association and the shareholders’ agreement. In practice, the two are often blurred, but they serve different functions. The articles govern the constitutional structure of the company: name, seat, purpose, share capital, shares, corporate bodies and the basic mechanics of decision-making. They are the formal foundation of the company and define the framework within which it can act at all.

The shareholders’ agreement goes much further. It is the document that governs the economic and strategic relationship between the shareholders with precision. In biotech, that matters because issues arise early that go well beyond a standard incorporation: vesting, leaver mechanics, share transfers, anti-dilution, reserved matters, information rights, exit mechanics and the admission of future investors. A later VSOP should also be contemplated early where key people are not intended to become shareholders immediately. In practice, the shareholders’ agreement is often the central governance document of a financeable biotech start-up.

The management layer is equally important. Once founders are not only shareholders but also managing directors, a mere appointment is usually not enough. A managing director service agreement is typically needed to regulate scope of responsibilities, compensation, allocation of tasks, reporting duties, confidentiality, IP-related obligations and the interface between the office and the contractual relationship. In biotech, this matters because operational decisions can quickly touch sensitive areas such as IP, grants, research partners, material transfer or regulatory preparation. The management role and personal exposure should therefore never be treated casually.

Biotech companies also need a second level of operational documentation. That typically includes employment agreements with clear IP and confidentiality provisions, freelancer and consultant agreements, development and collaboration agreements and, where needed, service or lab agreements. Especially with external contributors, it is not legally self-evident that newly created IP will vest fully in the company. That needs to be addressed expressly.

In Life Sciences, additional contract types often matter. If research materials, cell lines, plasmids or other biological materials are transferred, an MTA is often central. If confidential information is shared with investors, industry partners or potential licensees, a CDA should be put in place early. For existing and future founder rights, a Founder IP Assignment Agreement can be decisive in ensuring that relevant protection rights, know-how positions and other outputs are legally consolidated in the company. BIO.LAW’s toolkit provides practical templates for these situations.

What role do trade secret protection and operational discipline play?

In biotech, trade secret protection is often as important as formal patent protection.

Know-how, development data, assays, manufacturing details and experimental workflows are often among the company’s key value drivers. Those elements are only truly protected if the start-up not only understands them technically, but also secures them organizationally. Trade secret protection is therefore not just a matter of confidentiality clauses.

In practice, it usually also requires technical and organizational measures such as access restrictions, role concepts, internal policies, documentation standards and SOPs. In Life Sciences, those measures should not be postponed until investors or partners start asking for them.

What support is useful when building a biotech start-up?

Biotech founders should not treat technology, financing, IP and regulation as separate silos.

In practice, the build-out becomes much easier when the right sparring partners are involved early. That may include tech transfer teams, specialized lawyers, patent advisers, grant advisers, incubators, sector-specific networks, experienced investors and, where relevant, scientific or industrial mentors. In biotech, the interface between science, IP, financing and regulatory strategy is too complex to handle as an afterthought.

It can also be useful to work with existing templates and deeper guidance. Founders building a Life Sciences company often benefit from understanding not only incorporation issues, but also patent licensing, patent assignment and the interests of different stakeholders in licensing structures. BIO.LAW offers further materials on these topics, along with templates for CDA, MTA, Founder IP Assignment Agreements and due diligence preparation.

Which mistakes do biotech founding teams make most often?

The biggest mistakes rarely concern the idea itself. They usually arise where scientific progress is not translated into a sound business structure.

A common mistake occurs at the very beginning: the asset is not defined precisely enough. The team knows that “the technology” is promising, but not which patentable elements, datasets, assays, materials, SOPs, software or know-how components actually underpin the company. That uncertainty tends to surface later in diligence, financing and licensing discussions.

The next classic mistake concerns the chain of title. Founders often assume that scientific contributions, data or technical outputs will somehow end up in the start-up automatically. In biotech, that is risky. If founder IP, employee contributions, freelancer work or, where relevant, university or institutional IP are not allocated and secured properly, the problem emerges exactly where investors and strategic partners will examine the company most closely.

The pre-incorporation phase is also often underestimated. Many teams become operational before the company is formally incorporated and cleanly able to act. Consultants are engaged, materials procured, lab time booked or early discussions with investors and partners started, without clarity on who is acting legally and who bears which obligations. That is a classic source of avoidable liability exposure.

A further issue lies in the ownership structure. Biotech start-ups are often set up too broadly because early scientific contribution is quickly converted into equity. That may be understandable from a team perspective, but it often complicates later financing rounds. If the cap table, shareholders’ agreement, vesting and possible VSOP are not considered early, a well-meant founding structure can quickly become an obstacle for venture capital or strategic investors.

Problems also arise in the documentation layer. Articles and shareholders’ agreements are copied from generic templates without reflecting the logic of biotech. IP allocation, vesting, the managing director role, reserved matters, anti-dilution, material transfer or confidentiality are then addressed too late or only in fragments. This often only becomes visible once a financing round, license negotiation or due diligence process is already under way.

Finally, many biotech start-ups think about financing too generically. Instead of explaining clearly which milestone a round is supposed to fund, capital needs are framed too broadly. In biotech, that is rarely enough. Investors want to understand which risk is reduced by the capital and why that specific progress should make the business more attractive for the next round, a collaboration or a licensing path.

The most common mistakes are therefore not isolated errors. They are connected. Founders who do not treat asset, rights, structure, documents and financing as one integrated architecture usually create weaknesses exactly where biotech companies are later scrutinized most intensely.

Conclusion

A biotech start-up does not become financeable simply because the technology is exciting. It becomes financeable when technology, rights, team and development planning are turned into a robust company structure.

In practical terms, that means founders should first define the asset and the IP strategy around it. Next, they need to secure the chain of title and address pre-incorporation risk. Only then should they set up the company in a way that supports financing, with a legal form, cap table and shareholders’ agreement designed to carry future rounds rather than obstruct them. In parallel, the capital plan should be built around concrete value drivers, so that each round funds a clear reduction in technical, regulatory or commercial risk rather than simply keeping the business alive.

The key next steps are therefore:

1. Define the asset and the IP strategy clearly.

2. Review the chain of title and pre-incorporation risk.

3. Set up the legal form, cap table and shareholders’ agreement so they can support financing.

4. Tie funding rounds to concrete data and development milestones.

5. Prepare the core contracts for IP, management, employees, freelancers, investors and confidentiality early.

Founders who do this early improve more than their position in discussions with investors and partners. They also reduce the risk that a good biotech or Life Sciences technology will fail for structural reasons.